Osteoarthritis Enrollment Form

Fax: 909-284-9140
Phone: 909-266-0016
□ **Urgent Request**
Rep: ____________________

PATIENT INFORMATION

Please complete the following or ***send patient demographic sheet***
Patient Name ________________________________
Address ________________________________
Address 2 ________________________________
City, State, Zip ________________________________
Home Phone ____________ Mobile Phone ____________
DOB __________Last Four of SS __________ Gender _____
Language Preference ________________________________

PRESCRIBER INFORMATION

Prescriber Name ________________________________
DEA ________________________________
NPI ________________________________
Address ________________________________
City, State, Zip ________________________________
Phone ________________ Fax ______________________
Contact Person ________________________________

Insurance Information:

□ Demographic sheet □ Universal claim form □ Insurance cards

- Please include demographic sheet along with Universal Claim Form for insurance records or reimbursements (Attach Copies of cards)

Diagnostic Information

□ M17.0 Bilateral Osteoarthritis of Knees □ M17.11 Osteoarthritis of Right Knee □ M17.12 Osteoarthritis of Left Knee □ Other Diagnosis: ____________

Has patient been treated previously for this condition? □ Yes □ No Medication(s) failed: ________________________________

Is patient currently on therapy? □ Yes □ No Type/Medication(s): ________________________________

Will patient stop taking the above medication(s) before starting the new medication? □ Yes □ No If yes, How long should patient wait before starting new medication? ________________________________

Other medications patient is currently taking including OTC medications with dosage and directions (or fax medication profile):
____

Prescription

Medication & Directions	Alternate Dosing	Quantity	Refills
□ Euflexxa 20mg/2ml prefilled syringes □ 3 prefilled syringes □ 6 prefilled syringes			
Inject 2ml IA weekly x 3 weeks into □ Bilateral □ Left Knee □ Right Knee			
□ Hyalgan 29mg/2 ml prefilled syringes □ 3 prefilled syringes □ 6 prefilled syringes			
Inject 2ml IA weekly x 3 weeks into □ Bilateral □ Left Knee □ Right Knee			
□ Orthovisc 30mg/2ml □ 1 prefilled syringe □ 2 prefilled syringes			
Inject 2ml IA weekly x 3 weeks into □ Bilateral □ Left Knee □ Right Knee			
□ Supartz 25mg/2.5 ml prefilled syringes □ 3 prefilled syringes □ 6 prefilled syringes			
Inject 2ml IA weekly x 3 weeks into □ Bilateral □ Left Knee □ Right Knee			
□ Synvisc One 48mg/6ml prefilled syringes □1 prefilled syringe □2 prefilled syringes			
Inject 6ml IA one time only into □ Bilateral □ Left Knee □ Right Knee			
□ Synvisc 16mg/2 ml prefilled syringes □ 3 prefilled syringes □ 6 prefilled syringes			
Inject 2 ml IA weekly x 3 weeks into □ Bilateral □ Left Knee □ Right Knee			
□ Others			

Ship to: □ Patient □ Office □ Other ________________________ Date: ________________ Need by Date ________________

Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s) and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorizations forms and the receipt and submission of patient tab values and other patient data, in the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize the pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

□ Product Substitution permitted □ Dispense as Written

Prescriber's Signature: ________________________________Date: ______________________

CONFIDENTIALITY STATEMENT: This communication is intended for use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone